Venetoclax

Active Ingredient: Venetoclax
Form: Oral tablet
Brand Name: Venclexta
Generic Name: Ventax
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Venclexta is a targeted oral therapy jointly developed by AbbVie Inc. and Genentech (a member of the Roche Group). As a BCL-2 inhibitor, it promotes apoptosis (programmed cell death) in cancer cells and is FDA- and EMA-approved for the treatment of:

• Chronic lymphocytic leukemia (CLL)

• Small lymphocytic lymphoma (SLL)

• Certain types of acute myeloid leukemia (AML)

Specifically, Venclexta is indicated as monotherapy for patients with CLL who have a 17p deletion or TP53 mutation and have failed treatment with a B-cell receptor pathway inhibitor, or for those who have failed both chemotherapy and BCR inhibitors.

Dosage and Administration:
Treatment begins at 20 mg orally once daily and is gradually increased over 5 weeks to a target dose of 400 mg once daily. This dose ramp-up is designed to reduce the risk of tumor lysis syndrome (TLS). After reaching the maintenance dose, treatment continues until disease progression or intolerability.

Common Side Effects:
Neutropenia, diarrhea, nausea, anemia, fatigue, and upper respiratory tract infection.
Serious side effects may include pneumonia, febrile neutropenia, and tumor lysis syndrome.

Storage:
Store below 30°C in a cool, dry place, away from light and moisture. Keep out of reach of children.

Frequently Asked Questions

Q: What is the relationship between Venclexta and Venetoclax?
A: Venclexta is the brand name registered by the original manufacturer. Venetoclax is its active ingredient.

Q: Is the Venclexta sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic effect as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of the Venclexta generic version reliable?
A: Yes. We work with Ziska Pharmaceuticals, one of the leading pharmaceutical manufacturers in Bangladesh, with in-house R&D, production, and quality control laboratories. The company is internationally GMP-certified. You can purchase with confidence.

Q: How does Venclexta work, and who is it suitable for?
A: Venclexta is a BCL-2 inhibitor. BCL-2 is a protein that prevents cancer cells from undergoing apoptosis (natural cell death). By blocking BCL-2, the drug helps restore the self-destruct mechanism in cancer cells. It is most suitable for patients whose cancer involves this molecular target. If BCL-2 is not applicable in your case, refer to our guide “Comprehensive Leukemia Targeted Therapy Overview” to explore alternatives.

Disclaimer:
This information is for reference only. Treatment decisions should always be made in consultation with your physician and based on the official prescribing information and the latest medical research.

Drug Instructions (Package Insert):
Download Link